CN116421642A - Xinnaoqing preparation and its preparing process - Google Patents
Xinnaoqing preparation and its preparing process Download PDFInfo
- Publication number
- CN116421642A CN116421642A CN202310185888.XA CN202310185888A CN116421642A CN 116421642 A CN116421642 A CN 116421642A CN 202310185888 A CN202310185888 A CN 202310185888A CN 116421642 A CN116421642 A CN 116421642A
- Authority
- CN
- China
- Prior art keywords
- xinnaoqing
- vitamin
- microcapsule
- preparation
- sodium alginate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 46
- 238000000034 method Methods 0.000 title claims description 25
- 239000003094 microcapsule Substances 0.000 claims abstract description 77
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000011162 core material Substances 0.000 claims abstract description 36
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 24
- 239000000661 sodium alginate Substances 0.000 claims abstract description 24
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 24
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 21
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229940046009 vitamin E Drugs 0.000 claims abstract description 21
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 21
- 239000011709 vitamin E Substances 0.000 claims abstract description 21
- 235000019485 Safflower oil Nutrition 0.000 claims abstract description 20
- 235000005713 safflower oil Nutrition 0.000 claims abstract description 20
- 239000003813 safflower oil Substances 0.000 claims abstract description 20
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 19
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 16
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 16
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 16
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims abstract description 16
- 229960004853 betadex Drugs 0.000 claims abstract description 16
- 239000000463 material Substances 0.000 claims abstract description 12
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 210000004556 brain Anatomy 0.000 claims abstract description 10
- 229930003270 Vitamin B Natural products 0.000 claims abstract description 9
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 9
- 239000011720 vitamin B Substances 0.000 claims abstract description 9
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 7
- 239000001110 calcium chloride Substances 0.000 claims abstract description 7
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 7
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 10
- 229940116229 borneol Drugs 0.000 claims description 10
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 10
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 10
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000000265 homogenisation Methods 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 239000002639 bone cement Substances 0.000 abstract description 2
- 238000004132 cross linking Methods 0.000 abstract description 2
- 239000011780 sodium chloride Substances 0.000 abstract description 2
- 229960002668 sodium chloride Drugs 0.000 abstract description 2
- 235000002639 sodium chloride Nutrition 0.000 abstract description 2
- 239000003921 oil Substances 0.000 description 25
- 235000019198 oils Nutrition 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 238000003860 storage Methods 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 238000000859 sublimation Methods 0.000 description 3
- 230000008022 sublimation Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a heart and brain clearing preparation and a preparation method thereof, belonging to the technical field of traditional Chinese medicine preparations, wherein the preparation method is to take sodium alginate to dissolve in water to obtain sodium alginate solution; dissolving beta-cyclodextrin and calcium chloride in water, adding safflower oil, borneolum Syntheticum, vitamin E and vitamin B into the obtained solidified solution 6 Dispersing monoglyceride, dripping sodium alginate solution, and lyophilizing to obtain XINNAOQING microcapsule; the Xinnaoqing microcapsule is the Xinnaoqing preparation. According to the invention, a stable embedding structure is formed by selecting a specific amount of auxiliary materials and utilizing the mutual coordination of the beta-cyclodextrin, sodium alginate and sodium chloride, the core material is successfully embedded into the beta-cyclodextrin, and then the gel bone glue is formed by crosslinking the beta-cyclodextrin, so that the leakage of the core material in the prepared Xinnaoqing microcapsule is effectively prevented.
Description
Technical Field
The invention relates to preparation of a traditional Chinese medicine preparation, in particular to a Xinnaoqing preparation and a preparation method thereof.
Background
The heart and brain clearing agent is prepared from safflower oil, vitamin E and vitamin B 6 And borneol, etc., has the effects of promoting blood circulation to remove blood stasis, dredging collaterals and inducing resuscitation, is mainly used for treating qi stagnation and blood stasis, heart vessel obstruction, cerebral collaterals and other symptoms, and is clinically used for treating myocardial infarction, coronary atherosclerosis, hypertension, cerebral infarction and the like.
At present, the Xinnaoqing product is in a soft capsule form, and other dosage forms do not exist. The soft capsule preparation can wrap the effective components such as safflower oil, borneol and the like, and avoid oxidation and sublimation, thereby improving the stability of the Xinnaoqing. Meanwhile, the oil content (mainly safflower oil) in the effective components of the Xinnaoqing is high, and other dosage forms such as tablets, granules and the like are not easy to prepare. However, the soft capsule production process is relatively complex, the material cost is high, the equipment requirement is high, and the industrial production is not facilitated. In addition, the soft capsule is easy to decompose when being heated, and the old, children and dysphagia patients have inconvenient taking. Therefore, how to develop other formulations of Xinnaoqing products is always one of the important points of Xinnaoqing product research.
Disclosure of Invention
Aiming at the problems, the invention provides a heart and brain clearing preparation and a preparation method thereof.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
the heart and brain clearing preparation comprises the following raw materials in parts by weight: 390 parts of safflower oil, 3 parts of borneol, 17 parts of vitamin E and vitamin B 6 5 parts of beta-cyclodextrin 175-185 parts, sodium alginate 95-105 parts, calcium chloride 50-55 parts and monoglyceride 7-7.5 parts.
A preparation method of a Xinnaoqing preparation comprises the following steps:
dissolving sodium alginate in water to obtain sodium alginate solution;
dissolving beta-cyclodextrin and calcium chloride in water, adding safflower oil, borneolum Syntheticum, vitamin E and vitamin B into the obtained solidified solution 6 Dispersing monoglyceride, dripping sodium alginate solution, and lyophilizing to obtain XINNAOQING microcapsule;
the Xinnaoqing microcapsule is one of the Xinnaoqing preparations, and the Xinnaoqing preparation can also be other pharmaceutically acceptable dosage forms such as Xinnaoqing tablets, xinnaoqing granules and the like.
Further, safflower oil, borneol, vitamin E and vitamin B are added into the curing liquid 6 And monoglyceride is prepared by dispersing safflower oil, borneolum Syntheticum, vitamin E, and vitamin B 6 Mixing with monoglyceride to obtain core material, adding the core material into the solidifying solution, and dispersing。
Further, the core material is prepared from safflower oil, borneolum Syntheticum, vitamin E, and vitamin B 6 Grinding with monoglyceride, and mixing.
Further, the dispersion is uniform by adopting a homogeneous way.
Further, the homogenization adopts a high-pressure homogenization mode, and the pressure is 10-20 MPa.
Furthermore, in the process of dropwise adding sodium alginate solution, the sodium alginate solution is also required to be dropwise added while ultrasonic mixing is performed.
Further, the frequency of the ultrasonic wave is 30-40 kHz.
Further, the freeze drying is to take the embedding substance solution to be placed at the temperature of minus 40 ℃ for pre-freezing for 1 to 2 hours;
heating to-20 ℃ to sublimate and dry for 2-3 h;
heating to 25 ℃ and resolving and drying for 2-3 h.
Further, the Xinnaoqing microcapsule is matched with a proper amount of auxiliary materials, and is prepared into other pharmaceutically acceptable dosage forms such as granules, tablets and the like according to a related pharmaceutical preparation method.
The Xinnaoqing preparation and the preparation method thereof have the beneficial effects that:
according to the invention, a stable embedding structure is formed by selecting a specific amount of auxiliary materials and utilizing the mutual coordination of beta-cyclodextrin, sodium alginate and sodium chloride, the core material is successfully embedded into the beta-cyclodextrin, and then the gel bone glue is formed by crosslinking the beta-cyclodextrin, so that the leakage of the core material in the prepared Xinnaoqing microcapsule is effectively prevented;
the beta-cyclodextrin used in the invention has a hydrophobic cavity, which is a ring-shaped molecular structure, hydrophilic groups are distributed on the peripheral surface to form a hydrophilic region, a hollow part in the interior is distributed with a plurality of hydrophobic groups, and can form an inclusion complex with a micro-drop-shaped core material, and the micro-drop-shaped core material is placed in the central part to finish embedding;
further, the sodium alginate is crosslinked with the beta-cyclodextrin, and a compact structure is formed at the outer side of the beta-cyclodextrin embedded with the core material so as to wrap the microcapsule and prevent the formed Xinnaoqing microcapsule from cracking or the core material from leaking;
in addition, the sodium alginate can be crosslinked by calcium ions to form a reticular outermost gel skeleton, the gel skeleton has certain supporting effect and elasticity, and can prevent the prepared Xinnaoqing microcapsule from deforming, further prevent core materials (grease) in the Xinnaoqing microcapsule from leaking, and ensure that the prepared Xinnaoqing microcapsule can bear certain pressure and heat energy, thereby ensuring that the Xinnaoqing microcapsule can be used for preparing other dosage forms;
the heart-brain clearing microcapsule prepared by the invention has stable structure and can prevent the leakage of the core material in the microcapsule;
the heart-brain clearing microcapsule prepared by the invention can successfully embed core materials (active ingredients), prevent rancidity of safflower oil and sublimation of borneol, and further improve the storage stability of the heart-brain clearing preparation;
the heart-brain clearing microcapsule prepared by the invention has good oxidation resistance, and effectively solves the problems of leakage and deterioration of core materials.
Drawings
FIG. 1 is a graph showing the results of a moisture resistance test of microcapsules in experimental example 1 of the present invention;
FIG. 2 is a graph showing the results of the retention rate test of the core material during storage of the microcapsules of experimental example 1 of the present invention;
FIG. 3 is a graph showing the results of the microcapsule release test in example 1 of the present invention.
Detailed Description
The following description of the technical solution in the embodiments of the present invention is clear and complete. In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention, but the present invention may be practiced in other ways other than those described herein, and persons skilled in the art will readily appreciate that the present invention is not limited to the specific embodiments disclosed below.
Example 1 preparation method of Xinnaoqing preparation
The embodiment is a preparation method of a Xinnaoqing preparation, and the specific preparation process comprises the following steps:
1) Adding 100g of sodium alginate into 2L of water, stirring and dissolving to obtain sodium alginate solution;
2) 180g of beta-cyclodextrin and 52g of calcium chloride are added into 1L of water, and stirred and dissolved to obtain a curing liquid;
3) 390g of safflower oil is taken, and 3g of borneol, 17g of vitamin E and vitamin B are added 6 5g, grinding and uniformly mixing, uniformly stirring, and sieving to obtain a core material;
4) Adding core materials into the curing liquid, carrying out high-pressure homogenization and dispersion under the condition of 15MPa, dropwise adding sodium alginate solution, simultaneously dropwise adding sodium alginate solution, carrying out ultrasonic mixing under the condition of the frequency of 40kHz, and freeze-drying the obtained embedding substance solution to prepare the heart-brain-clearing microcapsule, wherein the mark is M1.
Wherein, the process curve of freeze drying is as follows:
taking the embedding substance solution, and pre-freezing for 1.5 hours at the temperature of minus 40 ℃;
heating to-20deg.C, and sublimation drying for 2.5 hr;
heating to 25 ℃ and resolving and drying for 2.5h.
5) The obtained Xinnaoqing microcapsule M1 can also be matched with a proper amount of auxiliary materials, and prepared into other pharmaceutically acceptable dosage forms such as granules, tablets and the like according to a related pharmaceutical preparation method.
Wherein, the Xinnaoqing granule is prepared by adding proper auxiliary materials such as adhesive, wetting agent and the like in the preparation process and adopting a dry granulation or wet granulation production process.
The Xinnaoqing tablet is prepared by granulating, then matching with auxiliary materials such as lubricant, disintegrating agent and the like, and tabletting; or directly mixing with adjuvants such as binder, lubricant, disintegrating agent, etc. without granulating, and tabletting.
Examples 2 to 5 preparation method of Xinnaoqing preparation
Examples 2 to 5 are the same as example 1, except that the raw materials and the process parameters are different, and the detailed descriptions are shown in table 1:
table 1 list of process parameters in examples 2 to 5
The other parts of examples 2 to 5 are the same as those of example 1.
Experimental example 1 Experimental determination
Comparative examples 1 to 4 are comparative experiments of the preparation process of the central brain clearing preparation of example 1, which differ only in that:
in step 2) of comparative example 1, only 100g of beta-cyclodextrin was added, and the resulting Xinnaoqing microcapsule was labeled DM1.
Only 50g of sodium alginate was added in step 1) of comparative example 2, and the obtained Xinnaoqing microcapsule was labeled DM2.
Only 25g of calcium chloride was added in step 2) of comparative example 3, and the resulting Xinnaoqing microcapsule was labeled DM3.
Only 180g of soluble starch was added in step 1) of comparative example 4, and the resulting Xinnaoqing microcapsule was labeled DM4.
Nine groups of samples were taken from the heart and brain clear microcapsules M1 to M5 and DM1 to DM4, and each group of samples was subjected to the following test, respectively.
A1, measuring oil content and embedding rate of microcapsule surface
The method for measuring the oil content on the surface of the microcapsule comprises the following steps: accurately weighing 5g (accurate to 0.0001 g) of the sample, spreading in a Buchner funnel, washing with diethyl ether, filtering, collecting filtrate, heating to remove diethyl ether, and drying at 60deg.C to constant weight to obtain microcapsule surface oil content;
microcapsule surface oil content (%) =microcapsule surface oil content ≡microcapsule sample weight×100%.
The method for measuring the total oil content of the microcapsule comprises the following steps: accurately weighing 5g (accurate to 0.0001 g) of the sample, soaking in 50mL diethyl ether at room temperature for 30min, performing ultrasonic crushing at room temperature for 15min, soaking at room temperature for 30min, centrifuging, collecting filtrate, heating to remove diethyl ether, and drying at 60deg.C to constant weight to obtain microcapsule total oil content;
total oil content of microcapsules (%) = total oil content of microcapsules +.f microcapsule sample weight x 100%.
Embedding rate (%) = (microcapsule total oil content-microcapsule surface oil content)/(microcapsule total oil content x 100%).
Wherein during the detection process, vitamin B is used 6 Is insoluble in diethyl ether and can not be extracted, while safflower oil, borneolum Syntheticum and vitamin E are dissolved in diethyl ether and can be extracted. Thus vitamin B was not examined during the test 6 But due to vitamin B 6 Grinding and mixing with safflower oil, borneolum Syntheticum, and other core materials such as vitamin E, and making into microcapsule with effect in removing vitamin B 6 Separate alone but instead are embedded with other core materials. Therefore, the vitamin B can be obtained by examining the embedding condition of safflower oil, borneol and vitamin E 6 Is embedded in the substrate. In summary, the oil content of the microcapsule surface and the total oil content of the microcapsule may be slightly lower than the actual one, but the embedding rate is consistent with the actual one.
The specific results are as follows:
table 2 table of results of measuring oil content and embedding rate of Xinnaoqing microcapsule surface
| Group of | Microcapsule surface oil content (%) | Total oil content of microcapsules (%) | Embedding ratio (%) |
| M1 | 3.85 | 50.92 | 92.44 |
| M2 | 3.87 | 51.01 | 92.41 |
| M3 | 3.89 | 50.64 | 92.32 |
| M4 | 3.84 | 50.82 | 92.44 |
| M5 | 3.81 | 50.47 | 92.45 |
| DM1 | 26.76 | 34.62 | 22.70 |
| DM2 | 13.85 | 44.79 | 69.08 |
| DM3 | 11.06 | 45.62 | 75.76 |
| DM4 | 5.89 | 48.67 | 87.90 |
As can be seen from Table 2, the prepared Xinnaoqing microcapsule has higher embedding rate, and the embedding rate is reduced by changing the types of auxiliary materials or reducing the dosage of the auxiliary materials, so that the embedding effect is poor.
A2 microcapsule flowability
10g of sample is led into a funnel, the sample falls on a horizontal circular plate below the funnel through the funnel, the sample is naturally piled up, the height h of the sample powder pile and the covering radius r of the sample powder pile are measured, and the repose angle theta is calculated according to a formula;
angle of repose θ=arctan (h/r).
TABLE 3 results list of measurement of repose angle of Xinnaoqing microcapsule
| Group of | M1 | M2 | M3 | M4 | M5 | DM1 | DM2 | DM3 | DM4 |
| Angle of repose (°) | 31.2 | 32.1 | 31.7 | 32.3 | 31.5 | 30.4 | 33.7 | 35.4 | 33.4 |
As can be seen from Table 3, the heart and brain clearing microcapsule prepared by the invention has smaller repose angle, small viscosity and good fluidity.
A3 moisture resistance of microcapsules
Accurately weighing about 10g of a sample by using an electronic analytical balance, measuring the added mass of the sample within a certain time under the conditions of room temperature and 80% humidity, and calculating the weight gain rate;
weight gain (%) = weight of sample increased ≡weight of sample x 100%.
The specific results are shown in Table 4 and FIG. 1.
TABLE 4 results list of moisture resistance measurements of Xinnaoqing microcapsules
| Group of | M1 | M2 | M3 | M4 | M5 | DM1 | DM2 | | DM4 |
| 0h | |||||||||
| 0％ | 0％ | 0％ | 0％ | 0％ | 0％ | 0％ | 0％ | 0％ | |
| 6h | 1.47％ | 1.52％ | 1.43％ | 1.46％ | 1.50％ | 1.71％ | 1.62％ | 1.65％ | 1.58％ |
| 12h | 2.79％ | 2.84％ | 2.74％ | 2.76％ | 2.81％ | 3.54％ | 3.31％ | 3.42％ | 3.29％ |
| 18h | 3.94％ | 3.99％ | 3.85％ | 3.87％ | 3.96％ | 5.12％ | 4.89％ | 4.96％ | 4.57％ |
| 24h | 4.47％ | 4.53％ | 4.44％ | 4.45％ | 4.52％ | 5.79％ | 5.54％ | 5.63％ | 5.25％ |
| 30h | 4.63％ | 4.69％ | 4.58％ | 4.61％ | 4.65％ | 6.14％ | 5.87％ | 6.02％ | 5.51％ |
| 36h | 4.69％ | 4.74％ | 4.62％ | 4.64％ | 4.71％ | 6.58％ | 6.08％ | 6.37％ | 5.68％ |
| 42h | 4.71％ | 4.76％ | 4.63％ | 4.65％ | 4.73％ | 6.72％ | 6.21％ | 6.50％ | 5.76％ |
For the microcapsule storage process, the wall material is weakened or even destroyed after absorbing water, the protection effect on the core material is lost, the permeability of the wall is increased, the core material is easier to contact with the outside, the safflower oil in the wall material is also easier to oxidize and rancid, and the borneol is easier to sublimate, so that the curative effect of the heart-brain-clearing microcapsule is greatly reduced; in addition, the strength of the microcapsule wall is weakened, and a large amount of core material can be released, so that the retention rate of the core material is continuously reduced, and the quality of the Xinnaoqing microcapsule is further influenced. As can be seen from fig. 1, the heart-brain clearing microcapsule prepared by the invention has good moisture resistance, can maintain the stability of the heart-brain clearing microcapsule and prevent leakage of the core material.
A4, determination of storage Property of microcapsule sample
The microcapsule surface oil content and the microcapsule total oil content were determined according to the methods described above.
Weighing a sample with a certain mass, measuring, wherein the total oil content of the microcapsule is A, the surface oil content of the microcapsule is B, measuring the surface oil content of the sample after being stored for a certain time to be C by adopting a microcapsule surface oil content measuring method, and calculating the core material retention rate in the sample storage process;
core retention (%) = (a-C)/(a-B) ×100%.
Samples were taken and placed in a closed container, stored in a constant temperature incubator at 40 ℃, and the oil content on the microcapsule surface was measured every 10 days, and the results are shown in Table 5 and FIG. 2.
TABLE 5 Table of results of core retention measurements during storage of Xinnaoqing microcapsules
| Group of | M1 | M2 | M3 | M4 | M5 | DM1 | DM2 | | DM4 |
| 0d | |||||||||
| 100％ | 100％ | 100％ | 100％ | 100％ | 100％ | 100％ | 100％ | 100％ | |
| 10d | 99.81％ | 99.72％ | 99.76％ | 99.75％ | 99.79％ | 97.12％ | 99.02％ | 99.19％ | 99.43％ |
| 20d | 99.58％ | 99.47％ | 99.54％ | 99.52％ | 99.56％ | 92.97％ | 95.89％ | 96.86％ | 97.02％ |
| 30d | 99.32％ | 99.26％ | 99.29％ | 99.27％ | 99.31％ | 87.99％ | 91.72％ | 92.45％ | 94.02％ |
| 40d | 98.84％ | 98.79％ | 98.81％ | 98.80％ | 98.83％ | 81.72％ | 85.53％ | 87.98％ | 91.07％ |
| 50d | 98.22％ | 98.15％ | 98.19％ | 98.17％ | 98.21％ | 72.67％ | 78.26％ | 81.37％ | 86.68％ |
| 60d | 97.49％ | 97.41％ | 97.45％ | 97.43％ | 97.47％ | 59.27％ | 68.72％ | 72.96％ | 78.97％ |
As can be seen from FIG. 2, the core retention of the samples is reduced to different degrees along with the extension of the storage time, but the core retention of the Xinnaoqing microcapsule prepared by the invention is relatively high, which indicates that the Xinnaoqing microcapsule prepared by the invention can maintain longer storage time and prevent the leakage of the core.
A5, determination of microcapsule drug release Performance
Vitamin E is used as a measurement index for measuring release performance, and the vitamin E is detected according to a high performance liquid chromatography detection method for measuring vitamin E recorded in the second part of Chinese pharmacopoeia 2020.
Preparing a reference substance solution: accurately weighing a proper amount of vitamin E reference substance, and adding tween water solution with concentration of 0.5wt% to prepare reference substance solution containing 20 mug of vitamin E per 1 mL.
Preparing a test solution: taking 1g of a sample, taking 5mL of solution according to a release degree measurement method (a first method of a second annex of the Chinese pharmacopoeia 2010 edition), filtering, and supplementing 5mL of water in a dissolution cup immediately by adopting a first method device of the dissolution degree measurement method (a second annex of the Chinese pharmacopoeia 2010 edition), taking 900mL of tween aqueous solution with the concentration of 0.5wt% as a release medium, operating according to the law at the rotating speed of 100 rpm, and taking the continuous filtrate as a sample solution when 1h, 2h, 4h, 6h, 8h and 10 h.
Assay: respectively precisely sucking 20 μl of the control solution and 20 μl of the sample solution, injecting into high performance liquid chromatograph, and calculating release (i.e. dissolution) of each gram at different times. The specific results are shown in Table 6 and FIG. 3.
TABLE 6 Table 6 results of measuring the drug release properties of Xinnaoqing microcapsules
| Group of | 0h | 1h | 2h | 4h | 6h | 8h | |
| M1 | |||||||
| 0％ | 29.3％ | 52.7％ | 73.9％ | 91.8％ | 98.7％ | 99.8 | |
| M2 | |||||||
| 0％ | 28.9％ | 52.5％ | 73.4％ | 91.2％ | 98.4％ | 99.7 | |
| M3 | |||||||
| 0％ | 29.7％ | 53.6％ | 74.4％ | 92.7％ | 99.2％ | 99.8 | |
| M4 | |||||||
| 0％ | 28.4％ | 51.8％ | 72.6％ | 90.7％ | 97.8％ | 99.9 | |
| M5 | |||||||
| 0％ | 28.6％ | 52.3％ | 73.3％ | 90.9％ | 98.2％ | 99.8 | |
| DM1 | |||||||
| 0％ | 42.7％ | 78.4％ | 97.9％ | 99.8％ | 99.8％ | 99.8 | |
| DM2 | |||||||
| 0％ | 39.3％ | 70.9％ | 90.4％ | 99.7％ | 99.7％ | 99.7 | |
| DM3 | |||||||
| 0％ | 37.9％ | 67.4％ | 87.4％ | 99.9％ | 99.9％ | 99.9 | |
| DM4 | |||||||
| 0％ | 32.7％ | 61.4％ | 81.9％ | 95.7％ | 99.8％ | 99.8％ |
As can be seen from fig. 3, the heart-brain-clearing microcapsule prepared by the invention has good release rate, a certain slow release effect and relatively stable release rate. Meanwhile, the heart and brain clearing microcapsule prepared by the invention does not cause the problem that the core material cannot be released. Therefore, the heart and brain clearing microcapsule prepared by the invention does not influence the drug effect.
It will be apparent that the described embodiments are only some, but not all, embodiments of the invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Claims (10)
1. The heart and brain clearing preparation is characterized by comprising the following raw materials in parts by weight: 390 parts of safflower oil, 3 parts of borneol, 17 parts of vitamin E and vitamin B 6 5 parts of beta-cyclodextrin 175-185 parts, sodium alginate 95-105 parts, calcium chloride 50-55 parts and monoglyceride 7-7.5 parts.
2. The method for preparing the Xinnaoqing preparation of claim 1, which is characterized by comprising the following steps:
dissolving sodium alginate in water to obtain sodium alginate solution;
dissolving beta-cyclodextrin and calcium chloride in water, adding safflower oil, borneolum Syntheticum, vitamin E and vitamin B into the obtained solidified solution 6 Dispersing monoglyceride, dripping sodium alginate solution, and lyophilizing to obtain XINNAOQING microcapsule;
the Xinnaoqing microcapsule is the Xinnaoqing preparation.
3. The method for preparing a Xinnaoqing preparation according to claim 2, wherein safflower oil, borneol, vitamin E and vitamin B are added into the solidified liquid 6 And monoglyceride is prepared by dispersing safflower oil, borneolum Syntheticum, vitamin E, and vitamin B 6 And uniformly mixing the core material with the monoglyceride to obtain a core material, and adding the core material into the curing liquid for dispersion.
4. The method for preparing XINNAOQING preparation according to claim 3, wherein the core material is safflower oil, borneolum Syntheticum, vitamin E, and vitamin B 6 Grinding with monoglyceride, and mixing.
5. The method for preparing a Xinnaoqing preparation according to any one of claims 2 to 4, wherein the dispersion is uniform by a homogeneous way.
6. The method for preparing a Xinnaoqing preparation according to claim 5, wherein the homogenization adopts a high-pressure homogenization mode, and the pressure is 10-20 MPa.
7. The method for preparing a Xinnaoqing preparation according to any one of claims 2-4 and 6, wherein in the process of dripping sodium alginate solution, the sodium alginate solution is also required to be dripping and simultaneously mixed by ultrasound.
8. The method for preparing a Xinnaoqing preparation according to claim 7, wherein the ultrasonic frequency is 30-40 kHz.
9. The method for preparing a Xinnaoqing preparation according to any one of claims 2 to 4, 6 and 8, wherein the freeze-drying is performed by taking the embedding substance solution and pre-freezing at-40 ℃ for 1 to 2 hours;
heating to-20 ℃ to sublimate and dry for 2-3 h;
heating to 25 ℃ and resolving and drying for 2-3 h.
10. The method for preparing a Xinnaoqing preparation according to any one of claims 2-4, 6 and 8, wherein the Xinnaoqing microcapsule is mixed with a proper amount of auxiliary materials and prepared into other pharmaceutically acceptable dosage forms such as granules, tablets and the like according to a related pharmaceutical preparation method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310185888.XA CN116421642A (en) | 2023-03-01 | 2023-03-01 | Xinnaoqing preparation and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310185888.XA CN116421642A (en) | 2023-03-01 | 2023-03-01 | Xinnaoqing preparation and its preparing process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116421642A true CN116421642A (en) | 2023-07-14 |
Family
ID=87082192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310185888.XA Pending CN116421642A (en) | 2023-03-01 | 2023-03-01 | Xinnaoqing preparation and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116421642A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102106891A (en) * | 2009-12-25 | 2011-06-29 | 神威药业有限公司 | Cardio-cerebral refreshing sustained-release soft capsules and preparation method thereof |
| CN107158059A (en) * | 2017-03-30 | 2017-09-15 | 神威药业集团有限公司 | Application of the cardio-cerebral refreshing composition in Infant Injury in White Matter medicine caused by preparing treatment and/or preventing chronic cerebral ischemia |
| CN110074456A (en) * | 2019-05-24 | 2019-08-02 | 江南大学 | A kind of peppermint oil gel beads and preparation method thereof |
| CN111249249A (en) * | 2020-02-14 | 2020-06-09 | 上海宇昂水性新材料科技股份有限公司 | Sodium alginate microsphere with coenzyme Q10 and preparation method thereof |
| CN114177847A (en) * | 2021-12-07 | 2022-03-15 | 罗莱生活科技股份有限公司 | Plant essential oil microcapsule and preparation method thereof |
| CN114272280A (en) * | 2021-12-30 | 2022-04-05 | 神威药业集团有限公司 | Extraction method of safflower oil and Xinnaoqing soft capsule |
-
2023
- 2023-03-01 CN CN202310185888.XA patent/CN116421642A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102106891A (en) * | 2009-12-25 | 2011-06-29 | 神威药业有限公司 | Cardio-cerebral refreshing sustained-release soft capsules and preparation method thereof |
| CN107158059A (en) * | 2017-03-30 | 2017-09-15 | 神威药业集团有限公司 | Application of the cardio-cerebral refreshing composition in Infant Injury in White Matter medicine caused by preparing treatment and/or preventing chronic cerebral ischemia |
| CN110074456A (en) * | 2019-05-24 | 2019-08-02 | 江南大学 | A kind of peppermint oil gel beads and preparation method thereof |
| CN111249249A (en) * | 2020-02-14 | 2020-06-09 | 上海宇昂水性新材料科技股份有限公司 | Sodium alginate microsphere with coenzyme Q10 and preparation method thereof |
| CN114177847A (en) * | 2021-12-07 | 2022-03-15 | 罗莱生活科技股份有限公司 | Plant essential oil microcapsule and preparation method thereof |
| CN114272280A (en) * | 2021-12-30 | 2022-04-05 | 神威药业集团有限公司 | Extraction method of safflower oil and Xinnaoqing soft capsule |
Non-Patent Citations (1)
| Title |
|---|
| 胡荣;罗先钦;励娜;王云红;杨荣平;: "丹参酮缓释微囊的制备工艺研究", 中草药, vol. 43, no. 11, 21 September 2012 (2012-09-21), pages 2173 - 2176 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11130823B2 (en) | Method for producing hydrogels | |
| CN107875136B (en) | Amoxicillin medicinal preparation and preparation method thereof | |
| KR102353040B1 (en) | How to treat constipation | |
| CN103006600B (en) | Benzenesulfonate amlodipine tablet and preparation method thereof | |
| CN108187129A (en) | A kind of absorbable gelatin styptic powder and preparation method thereof | |
| CN105148316B (en) | A kind of sterile adhesive bandage of zinc-base montmorillonite and its preparation method and application | |
| CN116421642A (en) | Xinnaoqing preparation and its preparing process | |
| CN106551911A (en) | A kind of stable pleasure is cut down for Buddhist nun's pharmaceutical composition and preparation method thereof | |
| CN1299753C (en) | Chinese medicinal composition, its preparation method and quality control method | |
| CN102309538B (en) | Compound lumbricus extract, and preparation process and composition thereof | |
| CN1857497A (en) | Erosion treating Chinese medicine ointment and its quality control method | |
| CN105496982B (en) | A kind of chitosan tablet and preparation method thereof | |
| CN105963260B (en) | A kind of preparation method of pH responsive types medicine microspheres and the pH responsive type medicine microspheres prepared by this method | |
| CN100409860C (en) | Rough gentian soft capsule for treating hepatic diseases | |
| Shi et al. | α-Glucosidase immobilization on calcium-sodium alginate-chitosan gel beads for inhibitory activity evaluation from traditional Chinese medicines | |
| CN112168850B (en) | Preparation method of hydrophilic seabuckthorn sterol | |
| CN113440571B (en) | Preparation method of kidney-tonifying and bone-strengthening capsule | |
| CN107233323A (en) | A kind of medicine for treating chronic gastritis, hyperhydrochloria and preparation method thereof | |
| CN116785252A (en) | Boletus edulis polysaccharide capsule and preparation method and application thereof | |
| CN1732926B (en) | Medicine contained soft capsule | |
| CN111944071A (en) | Preparation method of antineoplastic drug microcapsule | |
| CN115105476A (en) | Orlistat freeze-dried oral preparation and preparation process thereof | |
| CN100476427C (en) | Quality control method of Chinese medicine preparation for treating rheumatosis and pain | |
| CN116407518A (en) | Preparation method of pseudo-ginseng dragon's blood capsule | |
| EP3860572A1 (en) | Spherical beads for use in producing pharmaceutically active pellets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |